Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
8,908
archived clinical trials in
Renal Impairment / Chronic Kidney Disease

Pharmacokinetics of Immunosuppressants in Renal Transplant Candidates Who Have Undergone Laparoscopic Sleeve Gastrectomy
A Multicenter Pilot Study to Determine the Pharmacokinetics of Astagraf XL, Prograf and Mycophenolate Mofetil in Renal Transplant Candidates Who Have Undergone Laparoscopic Sleeve Gastrectomy
Status: Enrolling
Updated:  5/11/2015
University of Cincinnati
mi
from
Cincinnati, OH
Pharmacokinetics of Immunosuppressants in Renal Transplant Candidates Who Have Undergone Laparoscopic Sleeve Gastrectomy
A Multicenter Pilot Study to Determine the Pharmacokinetics of Astagraf XL, Prograf and Mycophenolate Mofetil in Renal Transplant Candidates Who Have Undergone Laparoscopic Sleeve Gastrectomy
Status: Enrolling
Updated: 5/11/2015
University of Cincinnati
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Opioids in Chronic Kidney Disease Patients Undergoing Hemodialysis
Clinical Trial Simulation Using ODE/PDE Hemodialysis Model for Quantifying Oxycodone's Removal in End-Stage Kidney Disease
Status: Enrolling
Updated:  5/21/2015
Oscar A. Linares, MD
mi
from
Dearborn, MI
Opioids in Chronic Kidney Disease Patients Undergoing Hemodialysis
Clinical Trial Simulation Using ODE/PDE Hemodialysis Model for Quantifying Oxycodone's Removal in End-Stage Kidney Disease
Status: Enrolling
Updated: 5/21/2015
Oscar A. Linares, MD
mi
from
Dearborn, MI
Click here to add this to my saved trials
Food Preparation Effects on Gut Bacteria in Patients on Peritoneal Dialysis
Effect of a Low AGE Diet on Human Microbiome
Status: Enrolling
Updated:  6/9/2015
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Food Preparation Effects on Gut Bacteria in Patients on Peritoneal Dialysis
Effect of a Low AGE Diet on Human Microbiome
Status: Enrolling
Updated: 6/9/2015
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Click here to add this to my saved trials
Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function
A Phase II Study of Gemcitabine, Paclitaxel, and Doxorubicin, With Pegfilgrastim for the Treatment of Patients With Metastatic Transitional Cell Carcinoma and Renal Insufficiency
Status: Enrolling
Updated:  6/19/2015
Ozark Health Ventures LLC dba Cancer Research for The Ozarks Springfield
mi
from
Springfield, MO
Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function
A Phase II Study of Gemcitabine, Paclitaxel, and Doxorubicin, With Pegfilgrastim for the Treatment of Patients With Metastatic Transitional Cell Carcinoma and Renal Insufficiency
Status: Enrolling
Updated: 6/19/2015
Ozark Health Ventures LLC dba Cancer Research for The Ozarks Springfield
mi
from
Springfield, MO
Click here to add this to my saved trials
Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function
A Phase II Study of Gemcitabine, Paclitaxel, and Doxorubicin, With Pegfilgrastim for the Treatment of Patients With Metastatic Transitional Cell Carcinoma and Renal Insufficiency
Status: Enrolling
Updated:  6/19/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function
A Phase II Study of Gemcitabine, Paclitaxel, and Doxorubicin, With Pegfilgrastim for the Treatment of Patients With Metastatic Transitional Cell Carcinoma and Renal Insufficiency
Status: Enrolling
Updated: 6/19/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
A Safety Study of Tocilizumab to Improve Transplant Rates in Highly Sensitized Patients Awaiting Kidney Transplantation
A Phase I/II Trial of Tocilizumab + Intravenous Immunoglobulin (IVIG) as Agents to Reduce Donor-Specific Anti-HLA Antibodies (DSA) and Improve Transplant Rates in Highly-HLA Sensitized Patients Awaiting Kidney Transplantation
Status: Enrolling
Updated:  7/8/2015
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
A Safety Study of Tocilizumab to Improve Transplant Rates in Highly Sensitized Patients Awaiting Kidney Transplantation
A Phase I/II Trial of Tocilizumab + Intravenous Immunoglobulin (IVIG) as Agents to Reduce Donor-Specific Anti-HLA Antibodies (DSA) and Improve Transplant Rates in Highly-HLA Sensitized Patients Awaiting Kidney Transplantation
Status: Enrolling
Updated: 7/8/2015
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
24 Hour Use of the Wearable Artificial Kidney
First 24 Hour Human Trial of the Wearable Artificial Kidney
Status: Enrolling
Updated:  7/13/2015
Univ of Washington
mi
from
Seattle, WA
24 Hour Use of the Wearable Artificial Kidney
First 24 Hour Human Trial of the Wearable Artificial Kidney
Status: Enrolling
Updated: 7/13/2015
Univ of Washington
mi
from
Seattle, WA
Click here to add this to my saved trials
Oxygen Desaturation During Hemodialysis
Oxygen Desaturation During Hemodialysis: Clinical Correlates and Association With Adverse Outcomes
Status: Enrolling
Updated:  7/15/2015
Renal Research Institute
mi
from
New York, NY
Oxygen Desaturation During Hemodialysis
Oxygen Desaturation During Hemodialysis: Clinical Correlates and Association With Adverse Outcomes
Status: Enrolling
Updated: 7/15/2015
Renal Research Institute
mi
from
New York, NY
Click here to add this to my saved trials
Reduced Calorie Diet Intervention in Kidney Transplant Recipients
Reduced Calorie Diet Intervention in Kidney Transplant Recipients
Status: Enrolling
Updated:  7/16/2015
Vanderbilt University Medical Center
mi
from
Nashville, TN
Reduced Calorie Diet Intervention in Kidney Transplant Recipients
Reduced Calorie Diet Intervention in Kidney Transplant Recipients
Status: Enrolling
Updated: 7/16/2015
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Evaluation of Catheter Placement for Renal Replacement Therapy in Patients With Acute Kidney Injury
Evaluation of Catheter Placement for Renal Replacement Therapy in Patients With Acute Kidney Injury- Assessment of Dialysis Adequacy and Infection Rates
Status: Enrolling
Updated:  7/20/2015
Brigham and Women's Hosp
mi
from
Boston, MA
Evaluation of Catheter Placement for Renal Replacement Therapy in Patients With Acute Kidney Injury
Evaluation of Catheter Placement for Renal Replacement Therapy in Patients With Acute Kidney Injury- Assessment of Dialysis Adequacy and Infection Rates
Status: Enrolling
Updated: 7/20/2015
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Cholecalciferol (Vitamin D3) Therapy in Chronic Kidney Disease (CKD) Subjects
Efficacy of Cholecalciferol (Vitamin D3) Therapy in Correcting Vitamin D Insufficiency and Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease: A Randomized, Placebo Controlled Pilot Study
Status: Enrolling
Updated:  7/20/2015
The Emory Clinic
mi
from
Atlanta, GA
Cholecalciferol (Vitamin D3) Therapy in Chronic Kidney Disease (CKD) Subjects
Efficacy of Cholecalciferol (Vitamin D3) Therapy in Correcting Vitamin D Insufficiency and Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease: A Randomized, Placebo Controlled Pilot Study
Status: Enrolling
Updated: 7/20/2015
The Emory Clinic
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Phase 2A Trial of FMX-8 Treatment for Anemia in Patients With ESRD on Hemodialysis HD
A Phase 2A, Uncontrolled, Open-labeled Trial to Evaluate the Effect of FMX-8 Treatment for Anemia in Patients With End Stage Renal Disease (ESRD) on Hemodialysis (HD)
Status: Enrolling
Updated:  7/21/2015
DaVita Arvada Dialysis Center
mi
from
Arvada, CO
A Phase 2A Trial of FMX-8 Treatment for Anemia in Patients With ESRD on Hemodialysis HD
A Phase 2A, Uncontrolled, Open-labeled Trial to Evaluate the Effect of FMX-8 Treatment for Anemia in Patients With End Stage Renal Disease (ESRD) on Hemodialysis (HD)
Status: Enrolling
Updated: 7/21/2015
DaVita Arvada Dialysis Center
mi
from
Arvada, CO
Click here to add this to my saved trials
A Phase 2A Trial of FMX-8 Treatment for Anemia in Patients With ESRD on Hemodialysis HD
A Phase 2A, Uncontrolled, Open-labeled Trial to Evaluate the Effect of FMX-8 Treatment for Anemia in Patients With End Stage Renal Disease (ESRD) on Hemodialysis (HD)
Status: Enrolling
Updated:  7/21/2015
DaVita Minneapolis Dialysis Unit
mi
from
Minneapolis, MN
A Phase 2A Trial of FMX-8 Treatment for Anemia in Patients With ESRD on Hemodialysis HD
A Phase 2A, Uncontrolled, Open-labeled Trial to Evaluate the Effect of FMX-8 Treatment for Anemia in Patients With End Stage Renal Disease (ESRD) on Hemodialysis (HD)
Status: Enrolling
Updated: 7/21/2015
DaVita Minneapolis Dialysis Unit
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
Status: Enrolling
Updated:  7/23/2015
Clinical Research Facility
mi
from
Birmingham, AL
Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
Status: Enrolling
Updated: 7/23/2015
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
Status: Enrolling
Updated:  7/23/2015
Clinical Research Facility
mi
from
Chula Vista, CA
Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
Status: Enrolling
Updated: 7/23/2015
Clinical Research Facility
mi
from
Chula Vista, CA
Click here to add this to my saved trials
Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
Status: Enrolling
Updated:  7/23/2015
Clinical Research Facility
mi
from
Los Angeles, CA
Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
Status: Enrolling
Updated: 7/23/2015
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
Status: Enrolling
Updated:  7/23/2015
Clinical Research Facility
mi
from
Los Gatos, CA
Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
Status: Enrolling
Updated: 7/23/2015
Clinical Research Facility
mi
from
Los Gatos, CA
Click here to add this to my saved trials
Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
Status: Enrolling
Updated:  7/23/2015
Clinical Research Facility
mi
from
New Haven, CT
Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
Status: Enrolling
Updated: 7/23/2015
Clinical Research Facility
mi
from
New Haven, CT
Click here to add this to my saved trials
Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
Status: Enrolling
Updated:  7/23/2015
Clinical Research Facility
mi
from
Miami, FL
Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
Status: Enrolling
Updated: 7/23/2015
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
Status: Enrolling
Updated:  7/23/2015
Clinical Research Facility
mi
from
Pembroke Pines, FL
Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
Status: Enrolling
Updated: 7/23/2015
Clinical Research Facility
mi
from
Pembroke Pines, FL
Click here to add this to my saved trials
Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
Status: Enrolling
Updated:  7/23/2015
Clinical Research Facility
mi
from
Chicago, IL
Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
Status: Enrolling
Updated: 7/23/2015
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
Status: Enrolling
Updated:  7/23/2015
Clinical Research Facility
mi
from
Chicago, IL
Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
Status: Enrolling
Updated: 7/23/2015
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
Status: Enrolling
Updated:  7/23/2015
Clinical Research Facility
mi
from
Flint, MI
Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
Status: Enrolling
Updated: 7/23/2015
Clinical Research Facility
mi
from
Flint, MI
Click here to add this to my saved trials
Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
Status: Enrolling
Updated:  7/23/2015
Clinical Research Facility
mi
from
Flushing, NY
Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
Status: Enrolling
Updated: 7/23/2015
Clinical Research Facility
mi
from
Flushing, NY
Click here to add this to my saved trials
Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
Status: Enrolling
Updated:  7/23/2015
Clinical Research Facility
mi
from
Orangeburg, SC
Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
Status: Enrolling
Updated: 7/23/2015
Clinical Research Facility
mi
from
Orangeburg, SC
Click here to add this to my saved trials
Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
Status: Enrolling
Updated:  7/23/2015
Clinical Research Facility
mi
from
Chattanooga, TN
Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
Status: Enrolling
Updated: 7/23/2015
Clinical Research Facility
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
Status: Enrolling
Updated:  7/23/2015
Clinical Research Facility
mi
from
Dallas, TX
Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
Status: Enrolling
Updated: 7/23/2015
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
Status: Enrolling
Updated:  7/23/2015
Clinical Research Facility
mi
from
Houston, TX
Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
Status: Enrolling
Updated: 7/23/2015
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
Status: Enrolling
Updated:  7/23/2015
Clinical Research Facility
mi
from
Burlington, VT
Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
Status: Enrolling
Updated: 7/23/2015
Clinical Research Facility
mi
from
Burlington, VT
Click here to add this to my saved trials
Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
Status: Enrolling
Updated:  7/23/2015
Research Site
mi
from
St Leonards,
Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
Status: Enrolling
Updated: 7/23/2015
Research Site
mi
from
St Leonards,
Click here to add this to my saved trials
Diabetic Kidney Disease: Influence of Exercise Therapy on Physical and Vascular Function.
Diabetic Kidney Disease: Influence of Exercise Therapy on Physical and Vascular Function.
Status: Enrolling
Updated:  7/23/2015
Univ of Minnesota
mi
from
Minneapolis, MN
Diabetic Kidney Disease: Influence of Exercise Therapy on Physical and Vascular Function.
Diabetic Kidney Disease: Influence of Exercise Therapy on Physical and Vascular Function.
Status: Enrolling
Updated: 7/23/2015
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
MRI Technical Development and Applications in Kidney Disease
Status: Enrolling
Updated:  7/23/2015
Center for Magnetic Resonance Research
mi
from
Minneapolis, MN
MRI Technical Development and Applications in Kidney Disease
Status: Enrolling
Updated: 7/23/2015
Center for Magnetic Resonance Research
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Single Oral Dose of Bevenopran in Patients With Varying Degrees of Renal Impairment
Phase 1, Non-Randomized, Parallel-Group, Open-Label Study to Characterize the Pharmacokinetics of a Single Oral Dose of Bevenopran in Patients With Varying Degrees of Renal Impairment Compared to Healthy Subjects
Status: Enrolling
Updated:  7/23/2015
DaVita Clinical Research: Denver Clinical Research Unit
mi
from
Lakewood, CO
Single Oral Dose of Bevenopran in Patients With Varying Degrees of Renal Impairment
Phase 1, Non-Randomized, Parallel-Group, Open-Label Study to Characterize the Pharmacokinetics of a Single Oral Dose of Bevenopran in Patients With Varying Degrees of Renal Impairment Compared to Healthy Subjects
Status: Enrolling
Updated: 7/23/2015
DaVita Clinical Research: Denver Clinical Research Unit
mi
from
Lakewood, CO
Click here to add this to my saved trials
Single Oral Dose of Bevenopran in Patients With Varying Degrees of Renal Impairment
Phase 1, Non-Randomized, Parallel-Group, Open-Label Study to Characterize the Pharmacokinetics of a Single Oral Dose of Bevenopran in Patients With Varying Degrees of Renal Impairment Compared to Healthy Subjects
Status: Enrolling
Updated:  7/23/2015
DaVita Clinical Research: Minneapolis Research Unit
mi
from
Minneapolis, MN
Single Oral Dose of Bevenopran in Patients With Varying Degrees of Renal Impairment
Phase 1, Non-Randomized, Parallel-Group, Open-Label Study to Characterize the Pharmacokinetics of a Single Oral Dose of Bevenopran in Patients With Varying Degrees of Renal Impairment Compared to Healthy Subjects
Status: Enrolling
Updated: 7/23/2015
DaVita Clinical Research: Minneapolis Research Unit
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Safety & Tolerability of Berinert® (C1 Inhibitor) Therapy to Prevent Rejection
A Phase I/II Trial to Evaluate the Safety & Tolerability of Berinert® (C1 Inhibitor) Therapy to Prevent Complement-Dependent, Antibody-Mediated Rejection Post-Transplant in Highly-HLA Sensitized Patients"
Status: Enrolling
Updated:  7/28/2015
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Safety & Tolerability of Berinert® (C1 Inhibitor) Therapy to Prevent Rejection
A Phase I/II Trial to Evaluate the Safety & Tolerability of Berinert® (C1 Inhibitor) Therapy to Prevent Complement-Dependent, Antibody-Mediated Rejection Post-Transplant in Highly-HLA Sensitized Patients"
Status: Enrolling
Updated: 7/28/2015
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Conventional Laparoscopic Versus Laparoendoscopic Single Site Donor Nephrectomy in Living Donor Kidney Transplantation
A Randomized, Prospective, Parallel Group Study of Conventional Laparoscopic Donor Nephrectomy (LDN) Versus Laparoendoscopic Single Site Donor Nephrectomy (LESS-DN) in Living Donor Kidney Transplantation
Status: Enrolling
Updated:  7/29/2015
NewYork-Presbyterian Hospital/Weill Cornell Medical Center
mi
from
New York, NY
Conventional Laparoscopic Versus Laparoendoscopic Single Site Donor Nephrectomy in Living Donor Kidney Transplantation
A Randomized, Prospective, Parallel Group Study of Conventional Laparoscopic Donor Nephrectomy (LDN) Versus Laparoendoscopic Single Site Donor Nephrectomy (LESS-DN) in Living Donor Kidney Transplantation
Status: Enrolling
Updated: 7/29/2015
NewYork-Presbyterian Hospital/Weill Cornell Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Lowering Salt Intake in Chronic Kidney Disease: A Pilot Randomized Crossover Trial
Lowering Salt Intake in Chronic Kidney Disease: A Pilot Randomized Crossover Trial
Status: Enrolling
Updated:  8/4/2015
Univ of North Carolina
mi
from
Chapel Hill, NC
Lowering Salt Intake in Chronic Kidney Disease: A Pilot Randomized Crossover Trial
Lowering Salt Intake in Chronic Kidney Disease: A Pilot Randomized Crossover Trial
Status: Enrolling
Updated: 8/4/2015
Univ of North Carolina
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Nebivolol Versus Sustained Release Metoprolol Succinate in Patients With Chronic Kidney Disease
Efficacy and Tolerability of Nebivolol Versus Sustained Release Metoprolol Succinate in Patients With Chronic Kidney Disease: A Single-center Randomized Trial.
Status: Enrolling
Updated:  8/4/2015
University of Michigan Health Systems
mi
from
Ann Arbor, MI
Nebivolol Versus Sustained Release Metoprolol Succinate in Patients With Chronic Kidney Disease
Efficacy and Tolerability of Nebivolol Versus Sustained Release Metoprolol Succinate in Patients With Chronic Kidney Disease: A Single-center Randomized Trial.
Status: Enrolling
Updated: 8/4/2015
University of Michigan Health Systems
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Delivery of Soluble Ferric Pyrophosphate (SFP) Via the Dialysate to Maintain Iron Balance in Hemodialysis Patients
A Prospective, Randomized, Open-label, Multi-center, Controlled Clinical Trial of the Safety and Efficacy of Physiological Iron Maintenance in End Stage Renal Disease (ESRD) Subjects by Delivery of Soluble Ferric Pyrophosphate (SFP) Via Hemodialysate
Status: Enrolling
Updated:  8/5/2015
RAI
mi
from
Los Angeles, CA
Delivery of Soluble Ferric Pyrophosphate (SFP) Via the Dialysate to Maintain Iron Balance in Hemodialysis Patients
A Prospective, Randomized, Open-label, Multi-center, Controlled Clinical Trial of the Safety and Efficacy of Physiological Iron Maintenance in End Stage Renal Disease (ESRD) Subjects by Delivery of Soluble Ferric Pyrophosphate (SFP) Via Hemodialysate
Status: Enrolling
Updated: 8/5/2015
RAI
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Delivery of Soluble Ferric Pyrophosphate (SFP) Via the Dialysate to Maintain Iron Balance in Hemodialysis Patients
A Prospective, Randomized, Open-label, Multi-center, Controlled Clinical Trial of the Safety and Efficacy of Physiological Iron Maintenance in End Stage Renal Disease (ESRD) Subjects by Delivery of Soluble Ferric Pyrophosphate (SFP) Via Hemodialysate
Status: Enrolling
Updated:  8/5/2015
University of Louisville - Kidney Disease Program
mi
from
Louisville, KY
Delivery of Soluble Ferric Pyrophosphate (SFP) Via the Dialysate to Maintain Iron Balance in Hemodialysis Patients
A Prospective, Randomized, Open-label, Multi-center, Controlled Clinical Trial of the Safety and Efficacy of Physiological Iron Maintenance in End Stage Renal Disease (ESRD) Subjects by Delivery of Soluble Ferric Pyrophosphate (SFP) Via Hemodialysate
Status: Enrolling
Updated: 8/5/2015
University of Louisville - Kidney Disease Program
mi
from
Louisville, KY
Click here to add this to my saved trials
Immunologic Abnormalities, Chronic Inflammation and Oxidative Stress in Chronic Kidney Disease
Immunologic Abnormalities, Chronic Inflammation and Oxidative Stress in Chronic Kidney Disease
Status: Enrolling
Updated:  8/5/2015
Beckman Laser Institute
mi
from
Irvine, CA
Immunologic Abnormalities, Chronic Inflammation and Oxidative Stress in Chronic Kidney Disease
Immunologic Abnormalities, Chronic Inflammation and Oxidative Stress in Chronic Kidney Disease
Status: Enrolling
Updated: 8/5/2015
Beckman Laser Institute
mi
from
Irvine, CA
Click here to add this to my saved trials
Immunologic Abnormalities, Chronic Inflammation and Oxidative Stress in Chronic Kidney Disease
Immunologic Abnormalities, Chronic Inflammation and Oxidative Stress in Chronic Kidney Disease
Status: Enrolling
Updated:  8/5/2015
University of California Medical Center: Dialysis Unit
mi
from
Orange, CA
Immunologic Abnormalities, Chronic Inflammation and Oxidative Stress in Chronic Kidney Disease
Immunologic Abnormalities, Chronic Inflammation and Oxidative Stress in Chronic Kidney Disease
Status: Enrolling
Updated: 8/5/2015
University of California Medical Center: Dialysis Unit
mi
from
Orange, CA
Click here to add this to my saved trials
Immunologic Abnormalities, Chronic Inflammation and Oxidative Stress in Chronic Kidney Disease
Immunologic Abnormalities, Chronic Inflammation and Oxidative Stress in Chronic Kidney Disease
Status: Enrolling
Updated:  8/5/2015
UCIMC Dialysis center
mi
from
Orange, CA
Immunologic Abnormalities, Chronic Inflammation and Oxidative Stress in Chronic Kidney Disease
Immunologic Abnormalities, Chronic Inflammation and Oxidative Stress in Chronic Kidney Disease
Status: Enrolling
Updated: 8/5/2015
UCIMC Dialysis center
mi
from
Orange, CA
Click here to add this to my saved trials
Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment
A Phase I, Multi-center, Non-randomized, Open Label, Parallel-group Study Evaluating the Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment Compared to a Control Group
Status: Enrolling
Updated:  8/7/2015
Clinical Research Facility
mi
from
Los Angeles, CA
Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment
A Phase I, Multi-center, Non-randomized, Open Label, Parallel-group Study Evaluating the Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment Compared to a Control Group
Status: Enrolling
Updated: 8/7/2015
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment
A Phase I, Multi-center, Non-randomized, Open Label, Parallel-group Study Evaluating the Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment Compared to a Control Group
Status: Enrolling
Updated:  8/7/2015
Clinical Research Facility
mi
from
Aurora, CO
Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment
A Phase I, Multi-center, Non-randomized, Open Label, Parallel-group Study Evaluating the Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment Compared to a Control Group
Status: Enrolling
Updated: 8/7/2015
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment
A Phase I, Multi-center, Non-randomized, Open Label, Parallel-group Study Evaluating the Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment Compared to a Control Group
Status: Enrolling
Updated:  8/7/2015
Clinical Research Facility
mi
from
St. Louis, MO
Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment
A Phase I, Multi-center, Non-randomized, Open Label, Parallel-group Study Evaluating the Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment Compared to a Control Group
Status: Enrolling
Updated: 8/7/2015
Clinical Research Facility
mi
from
St. Louis, MO
Click here to add this to my saved trials
Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment
A Phase I, Multi-center, Non-randomized, Open Label, Parallel-group Study Evaluating the Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment Compared to a Control Group
Status: Enrolling
Updated:  8/7/2015
Clinical Research Facility
mi
from
Lebanon, NH
Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment
A Phase I, Multi-center, Non-randomized, Open Label, Parallel-group Study Evaluating the Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment Compared to a Control Group
Status: Enrolling
Updated: 8/7/2015
Clinical Research Facility
mi
from
Lebanon, NH
Click here to add this to my saved trials
Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment
A Phase I, Multi-center, Non-randomized, Open Label, Parallel-group Study Evaluating the Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment Compared to a Control Group
Status: Enrolling
Updated:  8/7/2015
Clinical Research Facility
mi
from
Buffalo, NY
Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment
A Phase I, Multi-center, Non-randomized, Open Label, Parallel-group Study Evaluating the Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment Compared to a Control Group
Status: Enrolling
Updated: 8/7/2015
Clinical Research Facility
mi
from
Buffalo, NY
Click here to add this to my saved trials
Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment
A Phase I, Multi-center, Non-randomized, Open Label, Parallel-group Study Evaluating the Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment Compared to a Control Group
Status: Enrolling
Updated:  8/7/2015
mi
from
Edmonton,
Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment
A Phase I, Multi-center, Non-randomized, Open Label, Parallel-group Study Evaluating the Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment Compared to a Control Group
Status: Enrolling
Updated: 8/7/2015
mi
from
Edmonton,
Click here to add this to my saved trials
NGAL As An Aid for the Diagnosis of Acute Kidney Injury in Intensive Care
The NGAL Test™ As An Aid for the Diagnosis of AKI in an Intensive Care Population, US
Status: Enrolling
Updated:  8/10/2015
Massachusetts General Hospital
mi
from
Boston, MA
NGAL As An Aid for the Diagnosis of Acute Kidney Injury in Intensive Care
The NGAL Test™ As An Aid for the Diagnosis of AKI in an Intensive Care Population, US
Status: Enrolling
Updated: 8/10/2015
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials